Latest Blogs

Jun 30, 2022
Establishing a reputation of humility, collegiality, and kindness ensures that people can seek you out earlier than later, which can prevent many complications and delays in care.
Jun 10, 2022
Dr. Khalid El Bairi reports on the educational presentations and exciting directions for future research from a recent event organized by young professionals in Taroudant, Morocco.
Jun 10, 2022
At the launch of an innovative partnership to combine medical oncology, hematology, and hospice and palliative medicine into a single fellowship program, Dr. Ramy Sedhom shares perspectives on the value of combined training and the critical function of this new training pathway.
May 26, 2022
"Several valuable lessons can be learned from the Syrian conflict and the immense experience of the Syrian American Medical Society’s (SAMS) efforts, coordination, and contributions developing oncology centers in northern Syria," said Dr. M. Bassel Atassi.
Subscribe to this column

Peter Paul Yu, MD, FASCO, FACP

Peter Paul Yu, MD, FACP, FASCO, is the physician-in-chief at Hartford HealthCare Cancer Institute. He is a past president of ASCO, past chair of the Breakthrough Co-Host Committee, and currently serves on the CancerLinQ Board of Governors, as an associate editor of JCO Clinical Cancer Informatics, and on the JCO Oncology Practice editorial board. Follow Dr. Yu on Twitter @YupOnc.

Disclosure.

Apr 16, 2012
It seems that every nephew or niece of mine who has an engineering degree is busy creating the next killer app for a mobile device. Usually it starts with way cool technology, but comes up short in figuring out why enough users would want it or what a sustainable business model might be. On the...
Mar 11, 2012
In health care, we often find ourselves reacting to events rather than dictating them. Being cast in this undesirable position is often unavoidable when dealing with regulators and federal policy. However, the ability to foresee the need for change and thereby influence the direction of change is a...
Nov 20, 2011
This week the FDA decided to withdraw bevacizumab's indication for treatment of metastatic breast cancer. The earlier indication had been approved under FDA's accelerated approval process wherein final approval was conditional on the generation of confirmatory evidence based on clinical trials.
Nov 06, 2011
Let me start by mentioning 2 things I missed earlier about Day 1 of the ASCO HIT/EHRs Symposium.  In the session on Usability, Karen Bell, Chair of CCHIT, mentioned 3 areas where EHRs may impact malpractice risk; Communications, Documentation and Medical Errors. Each of these has the potential to...
Nov 06, 2011
The November 3rd edition of the NEJM features a Perspective article on drug shortages by Mandy Gatesman and Thomas J Smith (NEJM 365:18 page 163) that address many of the causative issues that underlie this growing national problem.  

Pages